Science AI Journal
Medicine · Research topic

Open research questions in Platelet Disorders and Treatments

466 gap statements mined from Platelet Disorders and Treatments papers in our 7.9M-paper local library, which holds 2,110 papers on the topic — drawn mostly from each paper's own stated research gap, future-work, challenge and limitation notes, and its abstract. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one.

Choosing where to publish on Platelet Disorders and Treatments? See the ranked Medicine journals.

What the literature leaves open

  • One notable limitation of this study is the age disparity between the PDD and control groups, with the control group having a significantly higher mean age (62 ± 8 years) compared to the PDD group (48 ± 14 years). A further important limitation of the present study is the lack of individual-level data on antidepressant treatment.

    Altered platelet function in persistent depressive disorder: a study of density subpopulations and fibrinogen binding · 2026 · DOI

  • Future research should focus on large-scale, multicenter, prospective studies comparing EV-miRNAs with circulating free miRNAs in carefully characterized pediatric cohorts of patients with ITP, including both newly diagnosed and chronic patients.

    MicroRNA cargo of extracellular vesicles as mediators of immune dysregulation in pediatric immune thrombocytopenia: from pathogenetic drivers to biomarkers · 2026 · DOI

  • The mechanism underlying the loss of detectable CEACAM-1 signal during platelet spreading remains to be elucidated. However, direct redistribution of CEACAM-1 from intracellular compartments to the platelet surface was not assessed and remains to be established. An important limitation of the present study is that the CEACAM-1L and CEACAM-1S isoforms were not distinguished.

    Differential Localization of CEACAM-1 in Distinct Platelet Populations · 2026 · DOI

  • These recommendations are made with the understanding that there is limited evidence to fully support their effectiveness. However, the benefits of platelet transfusions, particularly in cases of antiplatelet therapy-related dysfunction, remain controversial, with some studies suggesting that the risk of thrombotic events may outweigh the benefits of transfusion.

    The Role of Platelet Dysfunctions in the Pathogenesis of the Hemostatic-Coagulant System Imbalances · 2025 · DOI

  • Despite significant advances in understanding platelet biology, several critical gaps remain in the regulation of redox signaling.

    Redox Control in Platelet Activity and Therapy · 2025 · DOI

  • In addition, 19 non-PICO questions covering scenarios in which evidence was lacking or of low quality were answered by expert opinion using iterative Delphi surveys with panelist integration and refinement.

    ACVIM consensus statement on the treatment of immune thrombocytopenia in dogs and cats · 2024 · DOI

  • The immature platelet fraction (IPF), a parameter obtained by the Sysmex XN-1000V analyzer, is used in humans to differentiate between central (CEN) and peripheral (PER) thrombocytopenia (TP) but has not been evaluated in small animals.

    Utility of immature platelet fraction in the Sysmex XN-1000V for the differential diagnosis of central and peripheral thrombocytopenia in dogs and cats · 2024 · DOI

  • This lack of dedicated data represents an important gap in the literature, particularly given the high prevalence of vWD and its frequent incidental diagnosis during preoperative evaluation. In contrast, evidence regarding children with vWD remains scarce.

    Von Willebrand disease as a predictor of postoperative hemorrhagic complications in pediatric adenotonsillar surgery: a retrospective cohort study · 2026 · DOI

  • However, evidence for which comorbidities serve as ITP triggers has not been systematically evaluated.

    ACVIM consensus statement on the diagnosis of immune thrombocytopenia in dogs and cats · 2024 · DOI

  • These observations point to several potential shared mechanisms, including inflammatory pathways, that warrant further investigation.

    Altered platelet function in persistent depressive disorder: a study of density subpopulations and fibrinogen binding · 2026 · DOI

  • Evidence is lacking on effective immunosuppressive protocols, prognosis, and prognostic indicators.

    Treatment outcomes and prognostic indicators of primary immune thrombocytopenia in 31 cats: a multicenter retrospective study (2000-2023) · 2026 · DOI

  • While these results are compelling, prospective clinical trials are warranted to define the long‐term safety, durability, and optimal dosing of anti‐CD38 therapies in refractory ITP populations.

    Efficacy of CD38 ‐Targeted Therapy in Severe, Multi‐Agent Refractory Immune Thrombocytopenia: A Case Series · 2026 · DOI

  • Prospective randomized studies are warranted to confirm efficacy, define optimal treatment strategies and establish safety.

    Efficacy and Safety of Eltrombopag 25 Mg for the Management of Chemotherapy-Induced Thrombocytopenia in Patients with Solid Tumours: A Retrospective Comparative Study · 2026 · DOI

  • While platelets are known to possess antibacterial activity against MRSA, the underlying mechanisms remain incompletely understood.

    Induced pluripotent stem cell-derived platelets kill multidrug-resistant Staphylococcus aureus via Toll-like receptor 2-MyD88 signaling and immunoglobulin G/FcγRIIA engagement · 2026 · DOI

  • In addition, the MRSA-killing capacity of induced pluripotent stem cell-derived platelets (iPSC-PLTs), which we succeeded in producing ex vivo, has not been previously characterized.

    Induced pluripotent stem cell-derived platelets kill multidrug-resistant Staphylococcus aureus via Toll-like receptor 2-MyD88 signaling and immunoglobulin G/FcγRIIA engagement · 2026 · DOI

  • The complementary immunosuppressive mechanisms of BAFF/APRIL blockade and MSC-mediated immune regulation may provide synergistic disease control and warrant further investigation in larger clinical studies.

    Combined mesenchymal stem cells and telitacicept therapy for Evans syndrome refractory to various immunosuppressive: a case report · 2026 · DOI

  • Cross-sectional abnormalities cannot establish persistence; treatment-associated change cannot establish restoration; and clinical association cannot establish prediction.

    Beyond platelet response: toward an immune remission framework in immune thrombocytopenia · 2026 · DOI

  • We suggest that patients with isolated thrombocytopenia are subject to misclassification as ITP, and that the peripheral-blood smear is frequently abnormal, which can prevent this misclassification if carefully reviewed.

    The Challenge for a Correct Diagnosis of Refractory Thrombocytopenia: ITP or MDS with Isolated Thrombocytopenia? · 2024 · DOI

  • To our knowledge, this is a rarely reported presentation in a patient with a recent COVID-19 infection.

    Severe Thrombocytopenia Induced by Re‐Exposure to Piperacillin/Tazobactam: A Case Report in Critically Ill Patient With COVID ‐19 · 2026 · DOI

  • The study did not control for such factors, which could have informed postoperative outcomes.

    Impact of chronic thrombocytopenia on clinical outcomes after single-level anterior cervical discectomy and fusion: an analysis of the nationwide inpatient sample of the US · 2026 · DOI

  • Its maximum amplitude (MA) reflects final clot strength and may help assess bleeding risk, but its relation to platelet count in pregnancy is not well defined.

    Physiologic clot strength by thromboelastography at extremely low and normal platelet counts in thrombocytopenic pregnant patients · 2026 · DOI

  • These findings support further investigation of allo-HSCT and avatrombopag in patients with THPO mutation-associated CAMT.

    Avatrombopag as a novel salvage therapy for refractory thrombocytopenia in THPO-mutated congenital amegakaryocytic thrombocytopenia after allogeneic hematopoietic stem cell transplantation · 2026 · DOI

  • Further investigation into the signal transduction mechanism of the 5-HT4-like receptor in the circular 4.

    Stereochemical 2D NMR Assignment of Thietane, Synthesis and Antiplatelet Activity of Novel Thietane-Containing 1-Isobutylpurine-2,6-dione Derivatives as Potential GPIIb/IIIa Inhibitors · 2026 · DOI

  • While the collagen fiber orientation within the injury site in vivo has not been…

    Staying on Track: Collagen Fibers Orientation Strongly Affects Thrombi Formation at High Shear · 2026 · DOI

  • Inherited platelet disorders represent a prevalent but inadequately understood subset of bleeding diatheses, often with elusive causative genetics.

    Molecular diagnosis of inherited platelet disorder via a targeted whole-exome virtual gene panel: a 5-year institutional experience · 2026 · DOI

Most-cited papers in Platelet Disorders and Treatments

Most recent work

Find a gap in your own Platelet Disorders and Treatments sub-topic

This page shows what the Platelet Disorders and Treatments literature already flags as unresolved. To narrow it to your specific question, search the Research Gap Finder: the search is free with a free account and lists the papers closest to your topic first. Unlocking that topic (50 credits, charged once) fills the comparison table from our 7.9M-paper local library and writes the gaps from its rows.

Open the Research Gap Finder →

Related topics in Medicine

Artificial Intelligence in Healthcare and Education
4,869 open questions
Dementia and Cognitive Impairment Research
3,297 open questions
Cancer Immunotherapy and Biomarkers
2,687 open questions
Liver Disease Diagnosis and Treatment
2,481 open questions
Substance Abuse Treatment and Outcomes
2,366 open questions
Sports Performance and Training
2,276 open questions
Mosquito-borne diseases and control
2,124 open questions
Parkinson's Disease Mechanisms and Treatments
2,117 open questions
Open questions raised by papers listed on this page include: (1) The mechanism underlying the loss of detectable CEACAM-1 signal during platelet spreading remains to be elucidated (“Differential Localization of CEACAM-1 in Distinct Platelet Populations”, 2026); (2) This lack of dedicated data represents an important gap in the literature, particularly given the high prevalence of vWD and its frequent incidental diagnosis during preoperative evaluation (“Von Willebrand disease as a predictor of postoperative hemorrhagic…”, 2026); (3) Evidence is lacking on effective immunosuppressive protocols, prognosis, and prognostic indicators (“Treatment outcomes and prognostic indicators of primary immune thrombocytopenia…”, 2026); (4) While these results are compelling, prospective clinical trials are warranted to define the long‐term safety, durability, and optimal dosing of anti‐CD38 therapies in refractory ITP populations (“Efficacy of CD38 ‐Targeted Therapy in Severe, Multi‐Agent Refractory Immune…”, 2026); (5) Prospective randomized studies are warranted to confirm efficacy, define optimal treatment strategies and establish safety (“Efficacy and Safety of Eltrombopag 25 Mg for the Management of…”, 2026). 466 gap statements have been mined from Platelet Disorders and Treatments papers in our 7.9M-paper local library, which holds 2,110 papers on the topic; the gaps come from whichever of those papers state one. They are mostly the research gaps the authors state and the papers' abstracts, plus future-work, limitations and challenges passages. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 1,100,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? Acceptance odds for top, mid and open/emerging journals, in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck for prior publication across 7 sources and our local library.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

How Pre-Check worksHow AI Review works

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.